J. Molner AS announced a licensing agreement to broaden its reach in the United States. The agreement involves licensing rights for five approved generic topical pharmaceutical products. Molner will lead the effort to reintroduce these products to the US market and will commercialize the products.

Molner estimates that the products will be relaunched over the next eighteen months.